版本:
中国

BRIEF-FDA accepts Rigel's NDA for Tavalisse

June 19 Rigel Pharmaceuticals:

* FDA accepts Rigel's New Drug Application for Tavalisse™ (fostamatinib disodium) for the treatment of chronic ITP

* Says expects action date for FDA to complete its review will be April 17, 2018, under Prescription Drug User Fee Act​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐